Stock analysts at Ladenburg Thalmann, assumed coverage of shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) with Buy recommendation, according to their opinion released on September 11. Analysts at FBR Capital are sticking to their Outperform recommendation for the stock. However, on May 26, they lifted target price to $20 from the prior target set at $15. Analysts at FBR Capital, made their first call for this company shares with a Outperform rating, according to a research note that dated back to May 26.
For the period that ended November 15, 2019, the short interest in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) stock is on the down. The 3.48% decline could be an indication that investors and traders expect a growth in the share price, often as a result of an advancement in the business’ fundamentals. The average brokerage opinion at 1.5 suggests disposing off these shares. Between October 31 and November 15, the total count of shorted shares totalled 45.14 thousand. That number was 1,628 less shares compared with the total of 46.77 thousand shares in the space of prior two weeks, which suggests more traders or funds are betting that the company stock will move up. The average daily volume for ORMP at the November 15th settlement surged to 102,110, versus 31,920 at the October 31st report. That led days to cover to move at 1, a 31.75% decrease compared to the 1.465132 days to cover recorded at the prior short interest data release.
Let’s take a glimpse at some insider activity at Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) and observe the pattern. The earliest insider trade happened on 09/09/2019. Sank Leonard gathered a total of 25 thousand shares of the firm at average share price of $2.92. The total amount for the purchase was set at $73 thousand. On completing this exchange, the Director account balance was 592.01 thousand shares. The stock grew 95.89 percent from that insider purchase. On 07/18/2019, Sank Leonard, Director, did a purchase of 54.52 thousand shares at a price of $3.59 per share. This increased 195.72 thousand shares to the insider’s fortune and the stock experienced a 59.33 percent rally in price since the news became public. This exchange saw 567.01 thousand shares get into the Director account. On 07/11/2019, Director Sank Leonard recorded a purchase transaction valued at $4.25 thousand. The purchase at $3.22 a share has added 1.32 thousand shares into the insider’s portfolio position. Meanwhile, shares price witnessed 77.64 percent increase since the transaction reporting date. The company insider is left with 512.5 thousand shares remaining in the account. Friedman Aviad, who works as Director at the company, performed a purchase of 2.5 thousand shares in a transaction worth $12.38 thousand. The acquisition recorded on 08/09/2018 was priced at $4.95 per share. The stock price soared 15.56 percent since the transaction. Friedman Aviad currently holds a stake of 22.19 thousand in ORMP stock which is worth $126.93 thousand after the insider buying.
The stock is lingering around the initial support level of $5.07. After this, the following support is at the zone of $4.41. Up until the time the ORMP stock hit levels beyond the current one, bulls should have no alarm. In terms of its momentum, the stock’s RSI hit 85.34 on the daily chart, and this may be a cause for concern. In case the price goes below $4.41 level on closing basis, there may be more profit booking with the stock growing weaker. Still, getting to the $6.09 level may cause a pull-back move approaching $6.45 mark.
On December 02, 2019, Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares gained 29.71% or 1.31 points to close at $5.72 with a thin trading volume of 3.397 million shares. It opened the trading session at $5.05, the shares rose to $5.8 and dropped to $4.78, the range by which the price of stock traded the whole day. The company now has a market cap of $84.43 million and currently has 14.76 million outstanding shares. Oramed Pharmaceuticals Inc. (ORMP) stock has accumulated 79.87 percent of market value in 21 trading days.
ORMP stock’s trailing 3-year beta is 1.35, meaning there will be a greater rate of return, although posing a higher risk. The part of a firm’s profit given to each outstanding share of regular stock was -$0.87 share in the trailing 52 weeks. The stock’s value surged 90.67 percent year to date (YTD) compared to a rise of 39.51 percent in 52 week’s period. The firm’s shares are still trading 14.4 percent below its 1-year high of $5.00 and 146.89 percent up from 52-week low of $2.32. The average consensus ranking on the company is 1.5, on a ranging where 5 is equal to a consensus sell rating. In other words, the mean analyst recommendations are ranking this stock as a buy.
Oramed Pharmaceuticals Inc. has a 96.6% gross profit margin.
Past records have indicated that shares in Oramed Pharmaceuticals Inc. rose on 8 different earnings reaction days and we have yet to see whether this trend will play out and remain in place when the company reports upcoming earnings.